Matthew specialises in patent litigation, opinion work, supplementary protection certificates (SPCs), paediatric extensions and regulatory advice.
Matthew has a strong science background, holding a PhD in molecular immunology, meaning he gets to grips with the scientific facts of a case quickly.
A leading individual in Chambers and is a rising star in litigation, Matthew has particular experience of acting for clients in the pharmaeutical, biotech and life sciences sectors. He regularly co-ordinates pan-European litigation and has been involved in hearings in Germany, Netherlands, Belgium and Norway.
EU Guidance on biosimilar MAbs - what took so long?, Scrip Regulatory Affairs, pp 10-12, 17, July 2012
Neurim - EU Advocate General argues that supplementary protection certificates should be allowed for usage patents, Scrip Regulatory Affairs, p 5, 22, May 2012
Patent star
Life Sciences (IP/patent litigation) - Band 2: Matthew Royle frequently represents pharmaceutical manufacturers in contentious work regarding patent infringement claims, revocation actions and secondary use SPCs. Prior to his legal career he undertook a doctorate in medical microbiology. "A well-respected litigator." "Matthew Royle is clearly very clever and good at managing challenging situations."
Intellectual Property (patent litigation) - Band 3: Matthew Royle acts for pharmaceutical companies in patent litigation and also advises them on SPCs and regulation. He has taken a number of cases to the UK Supreme Court.
Life Sciences - IP/Patent Litigation: "A good litigator, with a good knowledge of the life sciences sector. He has a particular focus on the generics side."
Intellectual Property - Patent Litigation
"The Impact Case of the Year" for Actavis v ICOS case, where we acted for Mylan in relation to litigation on two patents relating to Lilly's blockbuster drug Cialis® (tadalafil).
Leading individual - Life Sciences: IP/Patent (band 3) and IP: patent litigation (band 4).
Leading individual - Life Sciences: IP/Patent litigation (Band 3): Matthew Royle frequently represents pharmaceutical manufacturers in contentious work regarding patent infringement claims, revocation actions and secondary use SPCs. A source says: "He is a very good patent litigator – sensible, pragmatic and a pleasure to work with."
Leading individual - Intellectual Property: Patent litigation (Band 4): Matthew Royle acts for pharmaceuticals companies in patent litigation and also advises them on SPCs and regulation. A source says: "He is a very good patent litigator - sensible, pragmatic and a pleasure to work with."
Leading individual - TMT: Pharmaceuticals and Biotech
Leading individual: litigation (Bronze): Matthew Royle is a canny and highly trained harvester of SPC extensions – a “well-known, longstanding presence in intellectual property”.
Leading individual: Patents
Patent star
For Pregabalin Supreme Court case
Leading individual - Intellectual Property: Patent Litigation (Band 4): Matthew Royle is a patent litigator and pharmaceuticals regulation expert with an academic background in medical microbiology. A source says: "He is a real hands-on partner in a lot of major cases."
Leading individual - Life Sciences: IP/Patent Litigation (Band 3): Matthew Royle is known for representing generic pharmaceutical manufacturers in high-stakes patent litigation such as patent revocation actions and disputes concerning contested SPCs. A source says: "He is a real hands-on partner in a lot of major cases."
Leading individual - Intellectual Property: Patent Litigation (Band 4): Matthew Royle is a rising life sciences patent litigator whose recent work has involved questions of secondary medical uses, dosage regimes and SPCs. A market commentator says he is "very strong on the science."
Leading individual - Life Sciences: IP/Patent Litigation (Band 3): Matthew Royle is distinguished for his representation of generic pharmaceutical manufacturers in high-value patent revocation actions and cases concerning SPCs. Sources note that he is "very strong on the science."
‘Rising star’ in litigation
A life sciences company on market formation dates in relation to orphan medicinal products.
A life sciences company on the validity of and expiry of supplementary protection certificates for a product launch.
A life sciences company on an EPO opposition in relation to a pharmaceutical.
A company dealing with commercialisation arrangements for university discoveries on a dispute between co-inventors in relation to a patent.
A life sciences company on data exclusivity in relation to a combination product in the context of a sale of that product.
von mehreren Autoren
What is the language of the UPC?
von mehreren Autoren
What confidentiality protection is available?
von Dr Paul England
von Nicholas Vollers
von mehreren Autoren
von mehreren Autoren
von mehreren Autoren
von Adrian Toutoungi und Rochelle Ampomah-Ababio
von mehreren Autoren
von Tim Strong und Helen Brannigan
von mehreren Autoren